Get the Daily Brief
Latest Biotech News
Compass posts second Phase III win – psychedelics stocks rally
Compass Pathways reported positive results from a second Phase III trial of its synthetic psilocybin therapy COMP360 for treatment‑resistant depression, with the high-dose arm showing...
Novartis signs big macrocycle pact: up to $1.8B with Unnatural Products
Novartis struck a research and licensing collaboration with Unnatural Products to apply UNP’s AI‑guided macrocyclic peptide platform against cardiovascular targets, a deal that could deliver up to...
Merck inks R&D tie with Mayo Clinic to pair clinical data and AI
Merck and the Mayo Clinic announced an R&D collaboration to combine Mayo Clinic Platform clinical and genomic datasets with Merck’s AI‑enabled virtual cell technologies to accelerate target...
Danaher to buy Masimo: $9.9B deal to bulk up diagnostics
Danaher Corp. agreed to acquire Masimo Corp. for $9.9 billion, offering $180 per share in cash — a 38% premium to Masimo’s prior close — to expand Danaher’s diagnostics and med‑tech footprint. The...
FDA accepts BMS protein degrader for review — regulatory milestone
The FDA accepted a Biologics License Application for Bristol Myers Squibb’s targeted protein degrader, formally initiating review, while separately issuing a rejection for a Disc Medicine rare...
Altesa raises $75M as Sanofi backs rhinovirus antiviral pivot
Altesa BioSciences closed a $75 million Series B round led by Forbion with participation from Sanofi to fund a Phase 2b study of vapendavir in COPD patients — a repositioning of a once‑failed...
FDA chief warns U.S. losing ground to China in early drug development
FDA Commissioner Marty Makary warned in a CNBC interview that the U.S. is falling behind China on early‑stage drug development, pointing to bottlenecks in hospital contracting, ethical reviews,...
FDA reverses course: Moderna flu vaccine accepted for review
The U.S. Food and Drug Administration told Moderna it will accept and review the company’s biologics license application for its mRNA influenza vaccine mRNA-1010, assigning a PDUFA target date of...
Psilocybin wins again: Compass edges toward regulatory filing
Compass Pathways reported a second positive Phase III readout for its synthetic psilocybin candidate COMP360 in treatment‑resistant depression, repeating efficacy seen in an earlier pivotal trial....
Altesa raises $75M — Sanofi joins Series B to back respiratory program
Altesa BioSciences closed a $75 million Series B to advance vapendavir, an oral antiviral it in‑licensed to prevent COPD exacerbations tied to rhinovirus infections; Forbion led the round and...
Korsana surfaces with $175M to pursue anti‑amyloid antibody
Korsana Biosciences emerged from stealth with $175 million in seed and Series A financing to develop KRSA‑028, a monoclonal antibody designed to clear amyloid‑beta plaques in Alzheimer’s disease...
Novartis bets big on macrocycles: UNP pact could top $1.8B
Novartis signed a research collaboration and licensing agreement with Unnatural Products (UNP) to apply UNP’s AI‑guided macrocyclic peptide platform toward cardiovascular disease targets. The deal...
Merck and Mayo Clinic link data and AI for drug discovery
Merck and Mayo Clinic announced a research and development collaboration to combine Mayo Clinic’s clinical and genomic datasets with Merck’s AI‑enabled virtual cell technologies to accelerate...
J&J pauses enrollment in mid‑stage Alzheimer’s trial with AC Immune
Johnson & Johnson halted patient recruitment in a mid‑stage trial of an Alzheimer’s candidate being developed with partner AC Immune. The pause prompted an approximately 10% decline in AC Immune’s...
Gene‑editing milestones: in vivo base editing reverses behavior — LNPs insert full gene into airway cells
Two independent advances sharpen the therapeutic promise of genetic medicines. A dual AAV split‑base‑editor system (TeABE) achieved targeted in‑vivo editing of Chd3 in mouse brain, reversing...
Protein AI and manufacturing: 1.4M validated models meet an LLM production fix
Researchers released PSBench, the largest curated collection of annotated protein structure models—1.4 million entries—with independent quality assessments to improve AI protein‑structure...
Regulatory showdown — FDA warns US losing ground while China speeds trial reviews
FDA Commissioner Marty Makary warned U.S. policymakers and industry that the country is losing competitiveness in early‑stage drug development to China, citing bottlenecks in hospital contracting,...
FDA reverses course: Moderna’s mRNA flu vaccine accepted for review
The U.S. Food and Drug Administration reversed a recent refusal-to-file and agreed to review Moderna’s mRNA seasonal influenza vaccine mRNA-1010, assigning a PDUFA target date of Aug. 5, 2026. The...
Psilocybin scores again — Compass nears FDA filing after second Phase III win
Compass Pathways reported positive results from a second pivotal Phase III trial of its synthetic psilocybin formulation COMP360 in treatment‑resistant depression, reinforcing earlier data and...
Novartis bets on macrocycles: Big-dollar pact to hunt cardiovascular targets
Novartis signed a discovery and licensing agreement with Unnatural Products (UNP) to deploy UNP’s AI-guided macrocyclic peptide platform against cardiovascular disease targets. Financial terms...